|
|
Volumn 15, Issue 4, 2016, Pages 219-221
|
|
Deuterated drugs draw heavier backing
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BMS 986144;
CHLORIDE CHANNEL AFFECTING AGENT;
CTP 656;
CTP 730;
DEUTERIUM;
DEUTETRABENAZINE;
DEXTROMETHORPHAN;
FLUORINE;
HEPACIVIRIN INHIBITOR;
IVACAFTOR;
LENALIDOMIDE;
LUMACAFTOR;
PIOGLITAZONE;
UNCLASSIFIED DRUG;
VX 984;
ADRENERGIC RECEPTOR AFFECTING AGENT;
TETRABENAZINE;
VESICULAR MONOAMINE TRANSPORTER;
ADRENOLEUKODYSTROPHY;
ANXIETY DISORDER;
COUGHING;
CYSTIC FIBROSIS;
DEPRESSION;
DISTRESS SYNDROME;
DRUG CLEARANCE;
DRUG COST;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG SAFETY;
GILLES DE LA TOURETTE SYNDROME;
HEPATITIS C;
HUMAN;
HYDROGEN BOND;
NONALCOHOLIC FATTY LIVER;
NOTE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RESTLESSNESS;
SOMNOLENCE;
TARDIVE DYSKINESIA;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG DESIGN;
HALF LIFE TIME;
METABOLISM;
NEUROCOGNITIVE DISORDERS;
RISK ASSESSMENT;
ADRENERGIC UPTAKE INHIBITORS;
CLINICAL TRIALS AS TOPIC;
DEUTERIUM;
DRUG APPROVAL;
DRUG DESIGN;
HALF-LIFE;
HUMANS;
NEUROCOGNITIVE DISORDERS;
RISK ASSESSMENT;
TETRABENAZINE;
VESICULAR MONOAMINE TRANSPORT PROTEINS;
|
|
EID: 84962408713
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2016.63 Document Type: Note |
|
Times cited : (199)
|
|
References (0)
|
